JPRN-UMIN000016624已完成2 期
Phase II study of gemcitabine plus nab-Pacletaxel as second-line therapy after FOLFIRINOX for advanced pancreatic cancer - 2nd-line nab-Ptx+Gem study
Gifu University Hospital0 个研究点目标入组 30 人开始时间: 2015年2月25日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Pulmonary fibrosis or interstitial pneumonia Watery stool Infection Uncontrolled diabetes mellitus Any serious complication Pregnancy
研究者
相似试验
已完成
2 期
Phase II study of Gemcitabine + nab-paclitaxel as first-line therapy for locally advanced pancreatic cancerlocally advanced unresectable pancreatic cancerJPRN-UMIN000016852Kurume university school of medicine24
已完成
不适用
A phase II study of gemcitabine and nab-paclitaxel followed by chemoradiotherapy with S-1 in patients with locally advanced pancreatic cancerJPRN-UMIN000026525Chiba Cancer Center30
已完成
不适用
Phase I/II study of Gemcitabine plus nab-paclitaxel and intraperitoneal paclitaxel for pancreas cancer with peritoneal metastasisThe patients with pancreatic cancer who have peritoneal metastasis diagnosed by staging laparoscopy or open laparotomy.JPRN-UMIN000018878Study group of pancreatic cancer with peritoneal metastasis48
已完成
不适用
Phase I/II study of gemcitabine and nab-paclitaxel with radiation therapy in patients with pancreatic cancer.pancreatic cancerJPRN-UMIN000017751Department of Surgery, Keio University School of Medicine30
进行中（未招募）
1 期
Phase I-II trial of gemcitabine plus nab-paclitaxel (GemBrax) followed by FOLFIRINOX as first-line treatment of patients with metastatic pancreatic adenocarcinoma - GABRINOXEUCTR2012-003678-13-FRInstitut Régional de Cancerologie de Montpellier - Val d’Aurelle118